Safety Profile of PT-141 (Bremelanotide)

Evidence Limitation: The provided evidence contains limited detailed safety information for PT-141/bremelanotide. The available data primarily consists of study titles and clinical trial registrations without full safety reports or detailed adverse event profiles.

Known Side Effects

Based on the available clinical trial evidence from completed Phase 2 and Phase 3 studies in premenopausal women, PT-141 has been evaluated for safety, though specific side effect profiles are not detailed in the provided evidence. The compound has progressed through multiple phases of clinical testing, suggesting an acceptable safety profile for regulatory advancement, but comprehensive adverse event data is not available in the current evidence set.

Contraindications and Precautions

The provided evidence does not contain specific contraindication information for PT-141. The clinical trials focused on premenopausal women with hypoactive sexual desire disorder and female sexual arousal disorder, but contraindications for other populations are not detailed.

Drug Interactions

No drug interaction data for PT-141 is available in the provided evidence.

Populations That Should Avoid PT-141

The clinical evidence provided is limited to studies in premenopausal women. Safety data for other populations, including:

Postmenopausal women
Men (though one review article mentions consideration for male sexual disorders)
Pediatric populations
Patients with cardiovascular conditions
Patients with other medical comorbidities

is not available in the current evidence set.

Clinical Context

The available evidence shows PT-141 has been studied in multiple completed clinical trials, including Phase 2 and Phase 3 studies, suggesting regulatory bodies have found the safety profile acceptable for continued investigation. However, the specific safety parameters, monitoring requirements, and risk-benefit considerations are not detailed in the provided materials.

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Patients should consult healthcare providers for personalized medical guidance regarding PT-141 use, contraindications, and safety monitoring.

Evidence Note: The safety profile presented here is limited by the available evidence, which lacks detailed adverse event reporting and comprehensive safety data from the referenced clinical trials.

PT-141